IL165932A0 - Osteopontin oligodendrocytes and myelination - Google Patents
Osteopontin oligodendrocytes and myelinationInfo
- Publication number
- IL165932A0 IL165932A0 IL16593204A IL16593204A IL165932A0 IL 165932 A0 IL165932 A0 IL 165932A0 IL 16593204 A IL16593204 A IL 16593204A IL 16593204 A IL16593204 A IL 16593204A IL 165932 A0 IL165932 A0 IL 165932A0
- Authority
- IL
- Israel
- Prior art keywords
- myelination
- osteopontin
- oligodendrocytes
- osteopontin oligodendrocytes
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/585—Integrins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Developmental Biology & Embryology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39103502P | 2002-06-25 | 2002-06-25 | |
GBGB0224017.4A GB0224017D0 (en) | 2002-06-25 | 2002-10-16 | Osteopontin oligodendrocytes and myelination |
PCT/US2003/019864 WO2004001014A2 (en) | 2002-06-25 | 2003-06-24 | Osteopontin, oligodendrocytes and myelination |
Publications (1)
Publication Number | Publication Date |
---|---|
IL165932A0 true IL165932A0 (en) | 2006-01-15 |
Family
ID=30001991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16593204A IL165932A0 (en) | 2002-06-25 | 2004-12-22 | Osteopontin oligodendrocytes and myelination |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1517695A4 (en) |
JP (1) | JP2005535313A (en) |
CN (1) | CN1662249A (en) |
AU (1) | AU2003278205B2 (en) |
BR (1) | BR0312042A (en) |
CA (1) | CA2489905A1 (en) |
IL (1) | IL165932A0 (en) |
MX (1) | MXPA04012803A (en) |
NO (1) | NO20045560L (en) |
RU (1) | RU2005101633A (en) |
WO (1) | WO2004001014A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005238092B2 (en) * | 2004-05-03 | 2010-06-17 | Peter Maccallum Cancer Institute | Methods for stem cell expansion and differentiation |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU773350B2 (en) * | 1999-04-15 | 2004-05-20 | Children's Medical Center Corporation | Methods and compositions for modulating an immune response |
UA85368C2 (en) * | 2001-05-17 | 2009-01-26 | Эплайд Рисьорч Системз Ерс Холдинг Н.В. | Use of osteopontin for the treatment and/or prevention of neurologic diseases |
WO2003046135A2 (en) * | 2001-11-21 | 2003-06-05 | The Board Of Trustees Of The Leland Stanford Junior University | Osteopontin-related compositions and methods |
-
2003
- 2003-06-24 JP JP2004516190A patent/JP2005535313A/en active Pending
- 2003-06-24 RU RU2005101633/15A patent/RU2005101633A/en not_active Application Discontinuation
- 2003-06-24 CA CA002489905A patent/CA2489905A1/en not_active Abandoned
- 2003-06-24 EP EP03742164A patent/EP1517695A4/en not_active Withdrawn
- 2003-06-24 AU AU2003278205A patent/AU2003278205B2/en not_active Ceased
- 2003-06-24 BR BR0312042-2A patent/BR0312042A/en not_active IP Right Cessation
- 2003-06-24 CN CN038147882A patent/CN1662249A/en active Pending
- 2003-06-24 WO PCT/US2003/019864 patent/WO2004001014A2/en active Search and Examination
- 2003-06-24 MX MXPA04012803A patent/MXPA04012803A/en not_active Application Discontinuation
-
2004
- 2004-12-20 NO NO20045560A patent/NO20045560L/en not_active Application Discontinuation
- 2004-12-22 IL IL16593204A patent/IL165932A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2003278205B2 (en) | 2008-01-24 |
AU2003278205A1 (en) | 2004-01-06 |
BR0312042A (en) | 2005-05-24 |
EP1517695A4 (en) | 2010-09-01 |
CN1662249A (en) | 2005-08-31 |
JP2005535313A (en) | 2005-11-24 |
EP1517695A2 (en) | 2005-03-30 |
NO20045560L (en) | 2004-12-20 |
WO2004001014A3 (en) | 2004-12-29 |
WO2004001014A2 (en) | 2003-12-31 |
MXPA04012803A (en) | 2005-06-08 |
RU2005101633A (en) | 2005-06-10 |
CA2489905A1 (en) | 2003-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1539941A4 (en) | Adzymes and uses thereof | |
AU2003279814A8 (en) | Fluid-handling apparatus and methods | |
EP1575495A4 (en) | Compounds and methods | |
EP1501544A4 (en) | Alcam and alcam modulators | |
EP1467916A4 (en) | Container and methods associated therewith | |
AU2003216221A1 (en) | Attachment and articles using same | |
GB2395952B (en) | Block copolymer and use thereof | |
IL165112A0 (en) | Variant integrinpolypeptides and thereof | |
AU2003231827A8 (en) | Pseudo-tissues and uses thereof | |
AU2003228355A8 (en) | Adipocytes and uses thereof | |
GB0320590D0 (en) | Fixing means and methods | |
AU2003302173A8 (en) | Spirotetrathiocarbamates and spirooxothiocarbamates | |
GB0228525D0 (en) | Polymers and their use | |
IL165932A0 (en) | Osteopontin oligodendrocytes and myelination | |
GB0224017D0 (en) | Osteopontin oligodendrocytes and myelination | |
EP1487547A4 (en) | Physical interaction means and related uses thereof | |
AU2003228397A8 (en) | Hausp-p53 interaction and uses thereof | |
GB0207624D0 (en) | Chemokine and uses thereof | |
AU2003216442A8 (en) | Enkurin and uses thereof | |
GB0203528D0 (en) | Process and composition | |
AU2003223357A8 (en) | Compounds and methods | |
GB0216530D0 (en) | Methods and means | |
GB0216529D0 (en) | Methods and means | |
GB0216755D0 (en) | Methods and means | |
GB0207414D0 (en) | Methods and means |